tiprankstipranks
Advertisement
Advertisement

CH:BSLN Stock Latest News

Company AnnouncementsBasilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs
18d ago
PremiumCompany Announcements
Basilea Wins CARB-X Funding Boost for First-in-Human Trial of Novel Antibiotic BAL2420
2M ago
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
PremiumCompany Announcements
Basilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs
4M ago
Basilea Pharmaceutica Earnings Call Highlights Pipeline Push
PremiumCompany Announcements
Basilea Pharmaceutica Earnings Call Highlights Pipeline Push
4M ago
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
PremiumCompany Announcements
Basilea boosts revenues, triples net cash as anti‑infective pipeline advances
4M ago
Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
PremiumCompany AnnouncementsBasilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment
6M ago
BSLN
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
Premium
Ratings
Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating
6M ago
Basilea Achieves Sales Milestone with Cresemba in Europe
Premium
Company Announcements
Basilea Achieves Sales Milestone with Cresemba in Europe
7M ago
Basilea Secures BARDA Funding for Novel Antibiotic Development
PremiumCompany Announcements
Basilea Secures BARDA Funding for Novel Antibiotic Development
9M ago
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
PremiumRatings
Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating
9M ago
Basilea Secures Additional BARDA Funding for Antifungal Development
PremiumCompany Announcements
Basilea Secures Additional BARDA Funding for Antifungal Development
9M ago
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
PremiumCompany Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
9M ago
BSLN
Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
PremiumCompany AnnouncementsBasilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges
10M ago
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
10M ago
BSLN
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
Premium
Company Announcements
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
10M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
10M ago
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
PremiumCompany Announcements
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
10M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
10M ago
PremiumCompany Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
10M ago
PremiumCompany AnnouncementsBasilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors
10M ago
Premium
Company Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
10M ago
Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation
Premium
Ratings
Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation
11M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >